References
1. Martins F, Sofiya L, Sykiotis GP, Lamine F, Maillard M, Fraga M, et al. Adverse effects of immune-checkpoint inhibitors: epidemiology, management and surveillance. Nat Rev Clin Oncol 2019;16:563-80.
2. Aguayo-Albasini JL, Flores-Pastor B, Soria-Aledo V. GRADE system: classification of quality of evidence and strength of recommendation. Cir Esp 2014;92:82-8.
3. De Martin E, Michot JM, Rosmorduc O, Guettier C, Samuel D. Liver toxicity as a limiting factor to the increasing use of immune checkpoint inhibitors. JHEP Rep: Innov Hepatol 2020;2:100170.
4. Ascierto PA, Del Vecchio M, Mandalá M, Gogas H, Arance AM, Dalle S, et al. Adjuvant nivolumab versus ipilimumab in resected stage IIIB-C and stage IV melanoma (CheckMate238): 4-year results from a multicentre, double-blind, randomised, controlled, phase 3 trial. Lancet Oncol 2020;21:1465-77.
5. Dougan M, Wang Y, Rubio-Tapia A, Lim JK. AGA clinical practice update on diagnosis and management of immune checkpoint inhibitor colitis and hepatitis: expert review. Gastroenterology 2021;160:1384-93.
6. De Martin E, Michot JM, Papouin B, Champiat S, Mateus C,Lambotte O, et al. Characterization of liver injury induced by cancer immunotherapy using immune checkpoint inhibitors. J Hepatol 2018;68:1181-90.
7. Wang DY, Salem JE, Cohen JV, Chandra S, Menzer C, Ye F, et al. Fatal toxic effects associated with immune checkpoint inhibitors: a systematic review and meta-analysis. JAMA Oncol 2018;4:1721-8.
8. Weissman S, Saleem S, Sharma S, Krupka M, Inayat F, Aziz M, et al. Incidence, mortality, and risk factors of immunotherapy-associated hepatotoxicity: a nationwide hospitalization analysis. Liver Res 2021;5:28-32.
9. Fu J, Li WZ, McGrath NA, Lai CW, Brar G, Xiang YQ, et al. Immune checkpoint inhibitor associated hepatotoxicity in primary liver cancer versus other cancers: a systematic review and meta-analysis. Front Oncol 2021;11:650292.
10. Cunningham M, Iafolla M, Kanjanapan Y, Cerocchi O, Butler M, Siu LL, et al. Evaluation of liver enzyme elevations and hepatotoxicity in patients treated with checkpoint inhibitor immunotherapy. PLOS ONE 2021;16:e0253070.
11. Chen C, Wu B, Zhang C, Xu T. Immune-related adverse events associated with immune checkpoint inhibitors: an updated comprehensive disproportionality analysis of the FDA adverse event reporting system. Int Immunopharmacol 2021;95:107498.
12. Institute USDoHaHSNNC. Common Terminology Criteria for Adverse Events (CTCAE) version 4.03.
13. Pu D, Yin L, Zhou Y, Li W, Huang L, Cai L, et al. Safety and efficacy of immune checkpoint inhibitors in patients with HBV/HCV infection and advanced-stage cancer: a systematic review. Medicine (Baltimore) 2020;99:e19013.
14. Finn RS, Qin S, Ikeda M, Galle PR, Ducreux M, Kim TY, et al. Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma. N Engl J Med 2020;382:1894-905.
15. Duffy AG, Ulahannan SV, Makorova-Rusher O, Rahma O, Wedemeyer H, Pratt D, et al. Tremelimumab in combination with ablation in patients with advanced hepatocellular carcinoma. J Hepatol 2017;66:545-51.
16. El-Khoueiry AB, Sangro B, Yau T, Crocenzi TS, Kudo M, Hsu C, et al. Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial. Lancet (Lond, Engl) 2017;389:2492-502.
17. Yau T, Kang YK, Kim TY, El-Khoueiry AB, Santoro A, Sangro B, et al. Efficacy and safety of nivolumab plus ipilimumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib: the CheckMate 040 randomized clinical trial. JAMA Oncol 2020;6:e204564.
18. Kelley RK, Sangro B, Harris W, Ikeda M, Okusaka T, Kang YK, et al. Safety, efficacy, and pharmacodynamics of tremelimumab plus durvalumab for patients with unresectable hepatocellular carcinoma: randomized expansion of a phase I/II study. J Clin Oncol 2021;39:2991-3001.
19. Finn RS, Ryoo BY, Merle P, Kudo M, Bouattour M, Lim HY, et al. Pembrolizumab as second-line therapy in patients with advanced hepatocellular carcinoma in KEYNOTE-240: a randomized, double-blind, phase III trial. J Clin Oncol 2020;38:193-202.
20. Gutiérrez-Larrañaga M, González-López E, Roa-Bautista A, Rodrigues PM, Díaz-González Á, Banales JM, et al. Immune checkpoint inhibitors: the emerging cornerstone in cholangiocarcinoma therapy? Liver Cancer 2021;10:545-60.
21. Zeng FL, Chen JF. Application of immune checkpoint inhibitors in the treatment of cholangiocarcinoma. Technol Cancer Res Treat 2021;20:15330338211039952.
22. Oh D, He A, Qin S, Chen L, Okusaka T, Vogel A, et al. A phase 3randomized, double-blind, placebo-controlled study of durvalumab in combination with gemcitabine plus cisplatin (GemCis) in patients (pts) with advanced biliary tract cancer (BTC): TOPAZ-1. J Clin Oncol 2022;40(4 Suppl):378.
23. Kelley RK, Ueno M, Yoo C, Finn RS, Furuse J, Ren Z, et al. Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet (Lond, Engl) 2023;401:1853-65.
24. Ioka T, Ueno M, Oh D, Fujiwara Y, Chen J, Doki Y, et al. Evaluation of safety and tolerability of durvalumab (D) with or without tremelimumab (T) in patients (pts) with biliary tract cancer (BTC). J Clin Oncol 2019;37:387.
25. EASL Clinical Practice Guidelines: drug-induced liver injury. J Hepatol 2019;70:1222-61.
26. Brahmer JR, Lacchetti C, Schneider BJ, Atkins MB, Brassil KJ, Caterino JM, et al. Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: American Society of Clinical Oncology Clinical Practice Guideline. J Clin Oncol 2018;36:1714-68.
27. Haanen J, Carbonnel F, Robert C, Kerr KM, Peters S, Larkin J, et al. Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2017;28:iv119-42.
28. Sangro B, Chan SL, Meyer T, Reig M, El-Khoueiry A, Galle PR. Diagnosis and management of toxicities of immune checkpoint inhibitors in hepatocellular carcinoma. J Hepatol 2020;72:320-41.
29. Danan G, Benichou C. Causality assessment of adverse reactions to drugs - I. A novel method based on the conclusions of international consensus meetings: application to drug-induced liver injuries. J Clin Epidemiol.1993;46:1323-30.
30. Hayashi PH, Lucena MI, Fontana RJ, Bjornsson ES, Aithal GP, Barnhart H, et al. A revised electronic version of RUCAM for the diagnosis of DILI. Hepatology (Baltimore, Md) 2022;76:18-31.
31. Londoño MC, Reig M. RETOINMUNO multidisciplinary clinical approach to cancer patients with immune-related adverse events induced by checkpoint inhibitors. Cancers 2020;12:3446.
32. Tsung I, Dolan R, Lao CD, Fecher L, Riggenbach K, Yeboah-Korang A, et al. Liver injury is most commonly due to hepatic metastases rather than drug hepatotoxicity during pembrolizumab immunotherapy. Aliment Pharmacol Therap 2019;50:800-8.
33. Rodriguez-Frias EA, Lee WM. Cancer chemotherapy II: atypical hepatic injuries. Clin Liver Dis 2007;11:663-76, viii.
34. Bahirwani R, Reddy KR. Drug-induced liver injury due to cancer chemotherapeutic agents. Semin Liver Dis 2014;34:162-71.
35. Riveiro-Barciela M, González-Sans D, Marmolejo D, Salcedo MT, Muñoz-Couselo E. Hepatic sinusoidal obstruction syndrome associated with nivolumab: an uncommon adverse event related to immune checkpoint inhibitors. J Gastrointest Liver Dis 2021;30:171-2.
36. Charvet E, Lheure C, Isnard C, Franck N, Kramkimel N, Vallet-Pichard A, et al. Hepatic sinusoidal obstruction syndrome induced by nivolumab in advanced melanoma: a case report. Ann Oncol 2020;31:661-2.
37. Gonzalez-Cao M, Puertolas T, Riveiro M, Muñoz-Couselo E, Ortiz C, Paredes R, et al. Cancer immunotherapy in special challenging populations: recommendations of the Advisory Committee of Spanish Melanoma Group (GEM). J Immunother Cancer 2021:9.
38. Zhang X, Zhou Y, Chen C, Fang W, Cai X, Zhang X, et al. Hepatitis B virus reactivation in cancer patients with positive Hepatitis B surface antigen undergoing PD-1 inhibition. J Immunother Cancer 2019;7:322.
39. Aceituno L, Bañares J, Ruiz-Ortega L, Callejo-Pérez A, Muñoz-Couselo E, Ortiz-Velez C, et al. The low incidence of viral hepatitis reactivation among subjects on immunotherapy reduces the impact of suboptimal screening rate. Front Med 2022;9:916213.
40. Bataller R, Cabezas J, Aller R, Ventura-Cots M, Abad J, Albillos A, et al. Alcohol-related liver disease. Clinical practice guidelines. Consensus document sponsored by AEEH. Gastroenterol Hepatol 2019;42:657-76.
41. EASL Clinical Practice Guidelines: autoimmune hepatitis. J Hepatol 2015;63:971-1004.
42. Zen Y, Yeh MM. Hepatotoxicity of immune checkpoint inhibitors: a histology study of seven cases in comparison with autoimmune hepatitis and idiosyncratic drug-induced liver injury. Mod Pathol 2018;31:965-73.
43. Gauci ML, Baroudjian B, Zeboulon C, Pages C, Poté N, Roux O, et al. Immune-related hepatitis with immunotherapy: are corticosteroids always needed? J Hepatol 2018;69:548-50.
44. Peeraphatdit TB, Wang J, Odenwald MA, Hu S, Hart J, Charlton MR. Hepatotoxicity from immune checkpoint inhibitors: a systematic review and management recommendation. Hepatology (Baltimore, Md) 2020;72:315-29.
45. Dearden H, Au L, Wang DY, Zimmer L, Eroglu Z, Smith JL, et al. Hyperacute toxicity with combination ipilimumab andanti-PD1 immunotherapy. Eur J Cancer (Oxf, Engl: 1990) 2021;153:168-78.
46. Cheung V, Gupta T, Payne M, Middleton MR, Collier JD, Simmons A, et al. Immunotherapy-related hepatitis: real-world experience from a tertiary centre. Frontline Gastroenterol 2019;10:364-71.
47. Bajwa R, Cheema A, Khan T, Amirpour A, Paul A, Chaughtai S, et al. Adverse effects of immune checkpoint inhibitors (programmed death-1 inhibitors and cytotoxic T-lymphocyte-associated protein-4 inhibitors): results of a retrospective study. J Clin Med Res 2019;11:225-36.
48. Sanz-Segura P, García-Cámara P, Fernández-Bonilla E, Arbonés-Mainar JM, Bernal Monterde V. Gastrointestinal and liver immune-related adverse effects induced by immune checkpoint inhibitors: a descriptive observational study. Gastroenterol Hepatol 2021;44:261-8.
49. Gauci ML, Baroudjian B, Bédérède U, Zeboulon C, Delyon J, Allayous C, et al. Severe immune-related hepatitis induced by immune checkpoint inhibitors: clinical features and management proposal. Clin Res Hepatol Gastroenterol 2021;45:101491.
50. Patrinely JR Jr, McGuigan B, Chandra S, Fenton SE, Chowdhary A, Kennedy LB, et al. A multicenter characterization of hepatitis associated with immune checkpoint inhibitors. Oncoimmunology 2021;10:1875639.
51. Riveiro-Barciela M, Trallero-Araguás E, Martínez-Valle F. Toxicities from immunotherapy: from clinical trials to real-world clinical practice. Med Clin (Barc) 2020;155:541-7.
52. Sawada K, Hayashi H, Nakajima S, Hasebe T, Fujiya M, Okumura T. Non-alcoholic fatty liver disease is a potential risk factor for liver injury caused by immune checkpoint inhibitor. J Gastroenterol Hepatol 2020;35:1042-8.
53. Romanski NA, Holmstroem RB, Ellebaek E, Svane IM. Characterization of risk factors and efficacy of medical management of immune-related hepatotoxicity in real-world patients with metastatic melanoma treated with immune checkpoint inhibitors. Eur J Cancer (Oxf, Engl: 1990) 2020;130:211-8.
54. Miller ED, Abu-Sbeih H, Styskel B, Nogueras Gonzalez GM, Blechacz B, Naing A, et al. Clinical characteristics and adverse impact of hepatotoxicity due to immune checkpoint inhibitors. Am J Gastroenterol 2020;115:251-61.
55. Riveiro-Barciela M, Barreira-Díaz A, Salcedo M, Callejo-Pérez A, Muñoz-Couselo E, Iranzo P, et al. A two-step algorithm avoids corticosteroids in two-thirds of cancer patients with severe immune-mediated hepatitis due to immune checkpoint inhibitors. J Hepatol 2023:78.
56. Chmiel KD, Suan D, Liddle C, Nankivell B, Ibrahim R, Bautista C, et al. Resolution of severe ipilimumab-induced hepatitis after antithymocyte globulin therapy. J Clin Oncol 2011;29:e237-40.
57. Riveiro-Barciela M, Muñoz-Couselo E, Fernandez-Sojo J, Diaz-Mejia N, Parra-López R, Buti M. Acute liver failure due to immune-mediated hepatitis successfully managed with plasma exchange: new settings call for new treatment strategies? J Hepatol 2019;70:564-6.
58. Manns MP, Woynarowski M, Kreisel W, Lurie Y, Rust C, Zuckerman E, et al. Budesonide induces remission more effectively than prednisone in a controlled trial of patients with autoimmune hepatitis. Gastroenterology 2010;139:1198-206.
59. Brattsand R. Overview of newer glucocorticosteroid preparations for inflammatory bowel disease. Can J Gastroenterol Hepatol 1990;4:407-14.
60. Vollmer O, Felten R, Mertz P, Lebrun-Vignes B, Salem JE, Arnaud L. Characterization of auto-immune hepatitis associated with the use of anti-TNF agents: an analysis of 389 cases in VigiBase. Autoimmunity Rev 2020;19:102460.
61. Dolladille C, Ederhy S, Sassier M, Cautela J, Thuny F, Cohen AA, et al. Immune checkpoint inhibitor rechallenge after immune-related adverse events in patients with cancer. JAMA Oncol 2020;6:865-71.
62. Bouhlel L, Doyen J, Chamorey E, Poudenx M, Ilie M, Gal J, et al. Occurrence and number of immune-related adverse events are independently associated with survival in advanced non-small-cell lung cancer treated by nivolumab. Bull Cancer (Paris) 2020;107:946-58.
63. Das S, Johnson DB. Immune-related adverse events and anti-tumor efficacy of immune checkpoint inhibitors. J Immunother Cancer 2019;7:306.
64. Shimozaki K, Sukawa Y, Beppu N, Kurihara I, Suzuki S, Mizuno R, et al. Multiple immune-related adverse events and anti-tumor efficacy: real-world data on various solid tumors. Cancer Manage Res 2020;12:4585-93.
65. Ziemer M, Koukoulioti E, Beyer S, Simon JC, Berg T. Managing immune checkpoint-inhibitor-induced severe autoimmune-like hepatitis by liver-directed topical steroids. J Hepatol 2017;66:657-9.
66. Spain L, Walls G, Messiou C, Turajlic S, Gore M, Larkin J. Efficacy and toxicity of rechallenge with combination immune checkpoint blockade in metastatic melanoma: a case series. Cancer Immunol Immunother 2017;66:113-7.
67. Pollack MH, Betof A, Dearden H, Rapazzo K, Valentine I, Brohl AS, et al. Safety of resuming anti-PD-1 in patients with immune-related adverse events (irAEs) during combined anti-CTLA-4 and anti-PD1 in metastatic melanoma. Ann Oncol 2018;29:250-5.
68. Santini FC, Rizvi H, Plodkowski AJ, Ni A, Lacouture ME, Gambarin-Gelwan M, et al. Safety and efficacy of re-treating with immunotherapy after immune-related adverse events inpatients with NSCLC. Cancer Immunol Res 2018;6:1093-9.
69. Simonaggio A, Michot JM, Voisin AL, Le Pavec J, Collins M, Lallart A, et al. Evaluation of readministration of immune checkpoint inhibitors after immune-related adverse events inpatients with cancer. JAMA Oncol 2019;5:1310-7.
70. Riveiro-Barciela M, Barreira-Díaz A, Vidal-González J, Muñoz-Couselo E, Martínez-Valle F, Viladomiu L, et al. Immune-related hepatitis related to checkpoint inhibitors: clinical and prognostic factors. Liver Internatl 2020;40:1906-16.
71. Li M, Sack JS, Rahma OE, Hodi FS, Zucker SD, Grover S. Outcomes after resumption of immune checkpoint inhibitor therapy after high-grade immune-mediated hepatitis. Cancer 2020;126:5088-97.
72. Riveiro-Barciela M, Barreira-Díaz A, Callejo-Pérez A, Muñoz-Couselo E, Díaz-Mejía N, Díaz-González Á, et al. Retreatment with immune checkpoint inhibitors after a severe immune-related hepatitis: results from a prospective multicenter study. Clin Gastroenterol Hepatol 2023;21:732-40.
73. Onoyama T, Takeda Y, Yamashita T, Hamamoto W, Sakamoto Y, Koda H, et al. Programmed cell death-1 inhibitor-related sclerosing cholangitis: a systematic review. World J Gastroenterol 2020;26:353-65.
74. Björnsson ES, Andrade RJ. Long-term sequelae of drug-induced liver injury. J Hepatol 2022;76:435-45.
75. Scoazec JY. Drug-induced bile duct injury: new agents, new mechanisms. Curr Opin Gastroenterol 2022;38:83-8.
76. Kashima J, Okuma Y, Shimizuguchi R, Chiba K. Bile duct obstruction in a patient treated with nivolumab as second-line chemotherapy for advanced non-small-cell lung cancer: a case report. Cancer Immunol Immunother 2018;67:61-5.
77. Pi B, Wang J, Tong Y, Yang Q, Lv F, Yu Y. Immune-related cholangitis induced by immune checkpoint inhibitors: a systematic review of clinical features and management. Eur J Gastroenterol Hepatol 2021;33:e858-67.
78. Koya Y, Shibata M, Shinohara N, Nebuya S, Oe S, Honma Y, et al. Secondary sclerosing cholangitis with hemobilia induced by pembrolizumab: case report and review of published work. Hepatol Res 2019;49:950-6.
79. Mizuno K, Ito T, Ishigami M, Ishizu Y, Kuzuya T, Honda T, et al. Real world data of liver injury induced by immune checkpoint inhibitors in Japanese patients with advanced malignancies. J Gastroenterol 2020;55:653-61.
80. Suda T, Kobayashi M, Kurokawa K, Matsushita E. Simultaneous occurrence of autoimmune pancreatitis and sclerosing cholangitis as immune-related adverse events of pembrolizumab. BMJ Case Rep 2021:14.
81. Fujii M, Ozato T, Mizukawa S, Nasu J, Kawai H, Fujioka SI, et al. A rare case of immunotherapy-induced cholangitis and gastritis. Clin J Gastroenterol 2020;13:1083-90.
82. Nabeshima S, Yamasaki M, Matsumoto N, Takaki S, Nishi Y, Kawamoto K, et al. Atezolizumab-induced sclerosing cholangitis in a patient with lung cancer: a case report. Cancer Treat Res Commun 2021;26:100270.
83. Gelsomino F, Vitale G, Ardizzoni A. A case of nivolumab-related cholangitis and literature review: how to look for the right tools for a correct diagnosis of this rare immune-related adverse event. Invest New Drugs 2018;36:144-6.
84. Tahboub Amawi AD, Tremaine WJ, Venkatesh SK. Pembrolizumab-induced sclerosing cholangitis. Clin Gastroenterol Hepatol 2022;20:e18.
85. Williams H, Aitchison R. Pembrolizumab-induced autoimmune haemolytic anaemia and cholangitis. BMJ Case Rep 2019:12.
86. Yoshikawa Y, Imamura M, Yamaoka K, Kosaka Y, Murakami E, Morio K, et al. A case with life-threatening secondary sclerosing cholangitis caused by nivolumab. Clin J Gastroenterol 2021;14:283-7.
87. Talbot S, MacLaren V, Lafferty H. Sclerosing cholangitis in a patient treated with nivolumab. BMJ Case Rep 2021;14:e241700.
88. Izumi H, Kodani M, Kurai J, Takeda K, Okazaki R, Yamane K, et al. Nivolumab-induced cholangitis in patients with non-small cell lung cancer: case series and a review of literature. Mol Clin Oncol 2019;11:439-46.
89. Hirasawa Y, Yoshimura K, Matsui H, Kubota Y, Ishida H, Arai J, et al. A case report on severe nivolumab-induced adverse events similar to primary sclerosing cholangitis refractory to immunosuppressive therapy. Medicine (Baltimore) 2021;100:e25774.
90. Hamoir C, de Vos M, Clinckart F, Nicaise G, Komuta M, Lanthier N. Hepatobiliary and pancreatic: nivolumab-related cholangiopathy. J Gastroenterol Hepatol 2018;33:1695.
91. Sato K, Hayashi M, Abe K, Fujita M, Takahashi A, Ohira H. Pembrolizumab-induced sclerosing cholangitis in a lung adenocarcinoma patient with a remarkable response to chemotherapy: a case report. Clin J Gastroenterol 2020;13:1310-4.
92. Cǎlugǎreanu A, Rompteaux P, Bohelay G, Goldfarb L, Barrau V, Cucherousset N, et al. Late onset of nivolumab-induced severe gastroduodenitis and cholangitis in a patient with stage IV melanoma. Immunotherapy 2019;11:1005-13.
93. Sawada K, Shonaka T, Nishikawa Y, Hasegawa K, Hayashi H, Hasebe T, et al. Successful treatment of nivolumab-related cholangitis with prednisolone: a case report and review of the literature. Intern Med (Tokyo, Japan) 2019;58:1747-52.
94. Ogawa K, Kamimura K, Terai S. Antiprogrammed cell death-1 immunotherapy-related secondary sclerosing cholangitis. Hepatology (Baltimore, Md) 2019;69:914-6.
95. Stuart L, Lambourne B, Turner P, Jones DEJ, Plummer R, Cresti N, et al. Pembrolizumab as a cause of cholangiopathy in a patient with metastatic melanoma. Hepatology (Baltimore, Md) 2020;71:2164-6.
96. Anderson B, Dawe DE. Nivolumab-induced secondary sclerosing cholangitis with deterioration despite immunosuppression. J Thorac Oncol 2019;14:e205-6.
97. Gelsomino F, Vitale G, D’Errico A, Bertuzzi C, Andreone P, Ardizzoni A. Nivolumab-induced cholangitic liver disease: a novel form of serious liver injury. Ann Oncol 2017;28:671-2.
98. Vitale G, Lamberti G, Comito F, Di Nunno V, Massari F, Morelli MC, et al. Anti-programmed cell death-1 and anti-programmed cell death ligand-1 immune-related liver diseases: from clinical pivotal studies to real-life experience. Expert Opin Biol Ther 2020;20:1047-59.
99. Takinami M, Ono A, Kawabata T, Mamesaya N, Kobayashi H, Omori S, et al. Comparison of clinical features between immune-related sclerosing cholangitis and hepatitis. Invest New Drugs 2021;39:1716-23.
100. Zen Y, Yeh MM. Checkpoint inhibitor-induced liver injury: a novel form of liver disease emerging in the era of cancer immunotherapy. Semin Diagn Pathol 2019;36:434-40.
101. Kawakami H, Tanizaki J, Tanaka K, Haratani K, Hayashi H, Takeda M, et al. Imaging and clinicopathological features of nivolumab-related cholangitis in patients with non-small cell lung cancer. Invest New Drugs 2017;35:529-36.
102. Zen Y, Chen YY, Jeng YM, Tsai HW, Yeh MM. Immune-related adverse reactions in the hepatobiliary system: second-generation check-point inhibitors highlight diverse histological changes. Histopathology 2020;76:470-80.
103. Gourari K, Catherine J, Garaud S, Kerger J, Lepida A, Georgala A, et al. A rare case of hepatic vanishing bile duct syndrome occurring after combination therapy with nivolumaband cabozantinib in a patient with renal carcinoma. Diagnostics (Basel, Switzerland) 2022;12:539.
104. Zhong YY, McLean L, Buckle A, Siva S, Tran B. Vanishing bile duct syndrome associated with pazopanib after progression on pembrolizumab. Can J Urol 2020;27:10339-41.
105. Gemelli M, Carbone M, Abbate MI, Mancin M, Zucchini N, Colonese F, et al. Vanishing bile duct syndrome following pembrolizumab infusion: case report and review of the literature. Immunotherapy 2022;14:175-81.
106. Moi L, Bouchaab H, Mederos N, Nguyen-Ngoc T, Perreau M, Fenwick C, et al. Personalized cytokine-directed therapy with tocilizumab for refractory immune checkpoint inhibitor-related cholangiohepatitis. J Thorac Oncol 2021;16:318-26.
107. Kataoka S, Moriguchi M, Okishio S, Takahashi A, Okuda K, Seko Y, et al. Re-administration of nivolumab after immune check-point inhibitor-induced cholangitis: the first reported case. Clin J Gastroenterol 2022;15:467-74.
108. Cheung VTF, Brain O. Immunotherapy induced enterocolitis and gastritis - what to do and when? Best practice & research. Clin Gastroenterol 2020;48-49:101703.
109. Soularue E, Lepage P, Colombel JF, Coutzac C, Faleck D, Marthey L, et al. Enterocolitis due to immune checkpoint inhibitors: a systematic review. Gut 2018;67:2056-67.
110. Gupta A, De Felice KM, Loftus EV Jr, Khanna S. Systematic review: colitis associated with anti-CTLA-4 therapy. Aliment Pharmacol Therap 2015;42:406-17.
111. Hughes MS, Zheng H, Zubiri L, Molina GE, Chen ST, Mooradian MJ, et al. Colitis after checkpoint blockade: a retrospective cohort study of melanoma patients requiring admission for symptom control. Cancer Med 2019;8:4986-99.
112. Verschuren EC, van den Eertwegh AJ, Wonders J, Slangen RM, van Delft F, van Bodegraven A, et al. Clinical, endoscopic, and histologic characteristics of ipilimumab-associated colitis. Clin Gastroenterol Hepatol 2016;14:836-42.
113. Shieh AC, Guler E, Pfau D, Radzinsky E, Smith DA, Hoimes C, et al. Imaging and clinical manifestations of immune checkpoint inhibitor-related colitis in cancer patients treated with monotherapy or combination therapy. Abdom Radiol (NewYork) 2020;45:3028-35.
114. Marthey L, Mateus C, Mussini C, Nachury M, Nancey S, Grange F, et al. Cancer immunotherapy with anti-CTLA-4 monoclonal antibodies induces an inflammatory bowel disease. J Crohn’s Colitis 2016;10:395-401.
115. Beck KE, Blansfield JA, Tran KQ, Feldman AL, Hughes MS, Royal RE, et al. Enterocolitis in patients with cancer after antibody blockade of cytotoxic T-lymphocyte-associated antigen 4. J Clin Oncol 2006;24:2283-9.
116. Geukes Foppen MH, Rozeman EA, van Wilpe S, Postma C, Snaebjornsson P, van Thienen JV, et al. Immune checkpoint inhibition-related colitis: symptoms, endoscopic features, histology and response to management. ESMO Open 2018;3:e000278.
117. Abu-Sbeih H, Ali FS, Luo W, Qiao W, Raju GS, Wang Y. Importance of endoscopic and histological evaluation in the management of immune checkpoint inhibitor-induced colitis. J Immunother Cancer 2018;6:95.
118. Cheung VTF, Gupta T, Olsson-Brown A, Subramanian S, Sasson SC, Heseltine J, et al. Immune checkpoint inhibitor-related colitis assessment and prognosis: can IBD scoring point the way? Br J Cancer 2020;123:207-15.
119. Favara DM, Spain L, Au L, Clark J, Daniels E, Diem S, et al. Five-year review of corticosteroid duration and complications in the management of immune checkpoint inhibitor-related diarrhoea and colitis in advanced melanoma. ESMO Open 2020:5.
120. Mooradian MJ, Wang DY, Coromilas A, Lumish M, Chen T, Giobbie-Hurder A, et al. Mucosal inflammation predicts response to systemic steroids in immune checkpoint inhibitor colitis. J Immunother Cancer 2020;8:e000451.
121. Alhatem A, Patel K, Eriksen B, Bukhari S, Liu C. Nivolumab-induced concomitant severe upper and lower gastrointestinal immune-related adverse effects. ACG Case Rep J 2019;6:e00249.
122. Mitchell KA, Kluger H, Sznol M, Hartman DJ. Ipilimumab-induced perforating colitis. J Clin Gastroenterol 2013;47:781-5.
123. Mohamed AA, Richards CJ, Boyle K, Faust G. Severe inflammatory ileitis resulting in ileal perforation in association with combination immune checkpoint blockade for metastatic malignant melanoma. BMJ Case Rep 2018;2018,bcr2018224913.
124. Trystram N, Laly P, Bertheau P, Baroudjian B, Aparicio T, Gornet JM. Haemorrhagic shock secondary to a diffuse ulcerative enteritis after Ipilimumab and Nivolumab treatment for metastatic melanoma: a case report. Ann Palliat Med 2022;11:837-42.
125. Mourad AP, De Robles MS. Chemoimmunotherapy-related enteritis resulting in a mechanical small bowel obstruction - a case report. Int J Surg Case Rep 2021;79:131-4.
126. Wang DY, Mooradian MJ, Kim D, Shah NJ, Fenton SE, Conry RM, et al. Clinical characterization of colitis arising from anti-PD-1 based therapy. Oncoimmunology 2019;8:e1524695.
127. Molina GE, Allen IM, Hughes MS, Zubiri L, Lee H, Mooradian MJ, et al. Prognostic implications of co-occurring dermatologic and gastrointestinal toxicity from immune checkpoint inhibition therapy for advanced malignancies: a retrospective cohort study. J Am Acad Dermatol 2020;82:743-6.
128. Nice L, Bycroft R, Wu X, Rai SN, Figg L, Bhandari S, et al. Assessment of hospitalization rates for immune-related adverse events with immune checkpoint inhibitors. J Oncol Pharm Pract 2021;27:1736-42.
129. Cooksley T, Gupta A, Al-Sayed T, Lorigan P. Emergency presentations in patients treated with immune checkpoint inhibitors. Eur J Cancer (Oxf, Engl: 1990) 2020;130:193-7.
130. Chen TW, Razak AR, Bedard PL, Siu LL, Hansen AR. A systematic review of immune-related adverse event reporting in clinical trials of immune checkpoint inhibitors. Ann Oncol 2015;26:1824-9.
131. Tang SQ, Tang LL, Mao YP, Li WF, Chen L, Zhang Y, et al. The pattern of time to onset and resolution of immune-related adverse events caused by immune checkpoint inhibitors in cancer: a pooled analysis of 23 clinical trials and 8436 patients. Cancer Res Treat 2021;53:339-54.
132. Sun X, Roudi R, Dai T, Chen S, Fan B, Li H, et al. Immune-related adverse events associated with programmed cell deathprotein-1 and programmed cell death ligand 1 inhibitors for non-small cell lung cancer: a PRISMA systematic review and meta-analysis. BMC Cancer 2019;19:558.
133. Hu Y, Gong J, Zhang L, Li X, Li X, Zhao B, et al. Colitis following the use of immune checkpoint inhibitors: a real-world analysis of spontaneous reports submitted to the FDA adverse event reporting system. Int Immunopharmacol 2020;84:106601.
134. Nuzzo PV, Pond GR, Abou Alaiwi S, Nassar AH, Flippot R, Curran C, et al. Conditional immune toxicity rate in patients with metastatic renal and urothelial cancer treated with immune checkpoint inhibitors. J Immunother Cancer 2020;8:e000371.
135. Owen CN, Bai X, Quah T, Lo SN, Allayous C, Callaghan S, et al. Delayed immune-related adverse events with anti-PD-1-based immunotherapy in melanoma. Ann Oncol 2021;32:917-25.
136. Michot JM, Lappara A, Le Pavec J, Simonaggio A, Collins M, De Martin E, et al. The 2016-2019 ImmunoTOX assessment board report of collaborative management of immune-related adverse events, an observational clinical study. Eur J Cancer (Oxf, Engl: 1990) 2020;130:39-50.
137. Institute USDoHaHSNNC. Common terminology criteria for adverse events (CTCAE). Version 5.0. 2017.
138. Puzanov I, Diab A, Abdallah K, Bingham CO 3rd, Brogdon C, Dadu R, et al. Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the Society for Immunotherapy of Cancer (SITC) Toxicity Management Working Group. J Immunother Cancer 2017;5:95.
139. Bishay K, Tandon P, Bourassa-Blanchette S, Laurie SA, McCurdy JD. The risk of diarrhea and colitis in patients with lung cancer treated with immune checkpoint inhibitors: a systematic review and meta-analysis. Curr Oncol (Toronto, Ont) 2020;27:e486-94.
140. Khoja L, Day D, Wei-Wu Chen T, Siu LL, Hansen AR. Tumour- and class-specific patterns of immune-related adverse events of immune checkpoint inhibitors: a systematic review. Ann Oncol 2017;28:2377-85.
141. De Velasco G, Je Y, Bossé D, Awad MM, Ott PA, Moreira RB, et al. Comprehensive meta-analysis of key immune-related adverse events from CTLA-4 and PD-1/PD-L1 inhibitors in cancer patients. Cancer Immunol Res 2017;5:312-8.
142. Collins M, Soularue E, Marthey L, Carbonnel F. Management of patients with immune checkpoint inhibitor-induced enterocolitis: a systematic review. Clin Gastroenterol Hepatol 2020;18,1393-403.e1391.
143. Bertrand A, Kostine M, Barnetche T, Truchetet ME, Schaeverbeke T. Immune related adverse events associated with anti-CTLA-4 antibodies: systematic review and meta-analysis. BMC Med 2015;13:211.
144. Xu H, Tan P, Zheng X, Huang Y, Lin T, Wei Q, et al. Immune-related adverse events following administration of anti-cytotoxic T-lymphocyte-associated protein-4 drugs: a comprehensive systematic review and meta-analysis. Drug Des Dev Therapy 2019;13:2215-34.
145. Witges K, Shafer LA, Zarychanski R, Abou-Setta AM, Rabbani R, Dingwall O, et al. Ipilimumab-induced enterocolitis: a systematic review and meta-analysis. Drug Saf 2020;43:1255-66.
146. Nahar KJ, Rawson RV, Ahmed T, Tattersall S, Sandanayake N, Kiely CJ, et al. Clinicopathological characteristics and management of colitis with anti-PD1 immunotherapy alone or in combination with ipilimumab. J Immunother Cancer 2020;8:e001488.
147. Schmerling RA, Buzaid AC, Haddad CK, Schutz FA, Kater FR, Pimenta J, et al. Immune manifestations with checkpoint inhibitors in a single Brazilian center: experience and literature review. Future Sci OA 2020;7:Fso655.
148. Wang PF, Chen Y, Song SY, Wang TJ, Ji WJ, Li SW, et al. Immune-related adverse events associated with anti-PD-1/PD-L1 treatment for malignancies: a meta-analysis. Front Pharmacol 2017;8:730.
149. Berti A, Bortolotti R, Dipasquale M, Kinspergher S, Prokop L, Grandi G, et al. Meta-analysis of immune-related adverse events in phase 3 clinical trials assessing immune checkpoint inhibitors for lung cancer. Crit Rev Oncol Hematol 2021;162:103351.
150. Sonpavde GP, Grivas P, Lin Y, Hennessy D, Hunt JD. Immune-related adverse events with PD-1 versus PD-L1 inhibitors: a meta-analysis of 8730 patients from clinical trials. Future Oncol (Lond, Engl) 2021;17:2545-58.
151. Cañete F, Mañosa M, Lobatón T, Mesonero F, Rodríguez-Lago I, Cabré E, et al. Nivolumab-induced immune-mediated colitis: an ulcerative colitis look-alike-report of new cases and review of the literature. Int J Colorect Dis 2019;34:861-5.
152. Miyashita H, Mikami T, Satoi S, Cruz C, Galsky MD. Incidence and risk of colitis with programmed death 1 versus programmed death ligand 1 inhibitors for the treatment of cancer. J Immunother (Hagerstown, Md: 1997) 2020;43:291-8.
153. Hofmann L, Forschner A, Loquai C, Goldinger SM, ZimmerL, Ugurel S, et al. Cutaneous, gastrointestinal, hepatic, endocrine, and renal side-effects of anti-PD-1 therapy. Eur J Cancer (Oxf, Engl: 1990) 2016;60:190-209.
154. Grimaud F, Penaranda G, Stavris C, Retornaz F, Brunel V, Cailleres S, et al. Adverse events induced by PD-1/PD-L1 inhibitors: a real-world single-centre experience with a management-based approach. Therap Clin Risk Manage 2021;17:669-77.
155. Sakellariou S, Papathanasiou E, Perdiki M, Sotiropoulou M, Zampeli E, Michopoulos S, et al. Histological diversity of anti-PD1-induced colitis. Histol Histopathol 2022;37:699-708.
156. Kiyohara Y, Uhara H, Ito Y, Matsumoto N, Tsuchida T, Yamazaki N. Safety and efficacy of nivolumab in Japanese patients with malignant melanoma: an interim analysis of a postmarketing surveillance. J Dermatol 2018;45:408-15.
157. Sternberg CN, Loriot Y, James N, Choy E, Castellano D, Lopez-Rios F, et al. Primary results from SAUL, a multinational single-arm safety study of atezolizumab therapy for locally advanced or metastatic urothelial or nonurothelial carcinoma of the urinary tract. Eur Urol 2019;76:73-81.
158. Ouyang T, Cao Y, Kan X, Chen L, Ren Y, Sun T, et al. Treatment-related serious adverse events of immune checkpoint inhibitors in clinical trials: a systematic review. Front Oncol 2021;11:621639.
159. Coutzac C, Adam J, Soularue E, Collins M, Racine A, Mussini C, et al. Colon immune-related adverse events: anti-CTLA-4 and anti-PD-1 blockade induce distinct immunopathological entities. J Crohn’s Colitis 2017;11:1238-46.
160. Hodi FS, Chiarion-Sileni V, Gonzalez R, Grob JJ, Rutkowski P, Cowey CL, et al. Nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone in advanced melanoma (Check-Mate 067): 4-year outcomes of a multicentre, randomised, phase 3 trial. Lancet Oncol 2018;19:1480-92.
161. Almutairi AR, McBride A, Slack M, Erstad BL, Abraham I. Potential immune-related adverse events associated with monotherapy and combination therapy of ipilimumab, nivolumab, and pembrolizumab for advanced melanoma: a systematic review and meta-analysis. Front Oncol 2020;10:91.
162. Zhou S, Khanal S, Zhang H. Risk of immune-related adverse events associated with ipilimumab-plus-nivolumab and nivolumab therapy in cancer patients. Therap Clin Risk Manage 2019;15:211-21.
163. Da L, Teng Y, Wang N, Zaguirre K, Liu Y, Qi Y, et al. Organ-specific immune-related adverse events associated with immune checkpoint inhibitor monotherapy versus combination therapy in cancer: a meta-analysis of randomized controlled trials. Front Pharmacol 2019;10:1671.
164. Mearns ES, Bell JA, Galaznik A, Puglielli SM, Cichewicz AB, Boulanger T, et al. Gastrointestinal adverse events with combination of checkpoint inhibitors in advanced melanoma: a systematic review. Melan Manage 2018;5:Mmt01.
165. Park R, Lopes L, Cristancho CR, Riano IM, Saeed A. Treatment-related adverse events of combination immune checkpoint inhibitors: systematic review and meta-analysis. Front Oncol 2020;10:258.
166. Shieh C, Chalikonda D, Block P, Shinn B, Kistler CA. Gastrointestinal toxicities of immune checkpoint inhibitors :a multicenter retrospective analysis. Ann Gastroenterol 2021;34:46-52.
167. Heppt MV, Amaral T, Kähler KC, Heinzerling L, Hassel JC, Meissner M, et al. Combined immune checkpoint blockade for metastatic uveal melanoma: a retrospective, multi-center study. J Immunother Cancer 2019;7:299.
168. Reese SW, Marchese M, McNabb-Baltar J. Insights from pharmacovigilance: gastrointestinal-related immune checkpoint inhibitor adverse events. Gastroenterology 2020;159,1195-200.e1191.
169. Larkin J, Hodi FS, Wolchok JD. Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N Engl J Med 2015;373:1270-1.
170. Grover S, Dougan M, Tyan K, Giobbie-Hurder A, Blum SM, Ishizuka J, et al. Vitamin D intake is associated with decreased risk of immune checkpoint inhibitor-induced colitis. Cancer 2020;126:3758-67.
171. Yao J, Li M, Zhang H, Ge Y, Weygant N, An G. Differential risks of immune-related colitis among various immune checkpoint inhibitor regimens. Int Immunopharmacol 2020;87:106770.
172. Wolchok JD, Neyns B, Linette G, Negrier S, Lutzky J, Thomas L, et al. Ipilimumab monotherapy in patients with pre-treated advanced melanoma: a randomised, double-blind, multicentre, phase 2, dose-ranging study. Lancet Oncol 2010;11:155-64.
173. Ascierto PA, Del Vecchio M, Robert C, Mackiewicz A, Chiarion-Sileni V, Arance A, et al. Ipilimumab 10 mg/kg versus ipilimumab 3 mg/kg in patients with unresectable or metastatic melanoma: a randomised, double-blind, multicentre, phase 3 trial. Lancet Oncol 2017;18:611-22.
174. Wang Y, Abu-Sbeih H, Mao E, Ali N, Ali FS, Qiao W, et al. Immune-checkpoint inhibitor-induced diarrhea and colitis in patients with advanced malignancies: retrospective review at MD Anderson. J Immunother Cancer 2018;6:37.
175. Shao J, Wang C, Ren P, Jiang Y, Tian P, Li W. Treatment - and immune - related adverse events of immune checkpoint inhibitors in advanced lung cancer. Biosci Rep 2020;40.BSR20192347.
176. Yang W, Men P, Xue H, Jiang M, Luo Q. Risk of gastrointestinal adverse events in cancer patients treated with immune checkpoint inhibitor plus chemotherapy: a systematic review and meta-analysis. Front Oncol 2020;10:197.
177. Tian Y, Zhang Z, Yang X, Li D, Zhang L, Li Z, et al. The risk ratio of immune-related colitis, hepatitis, and pancreatitis in patients with solid tumors caused by PD-1/PD-L1inhibitors: a systematic review and meta-analysis. Front Oncol 2020;10:261.
178. Gao L, Yang X, Yi C, Zhu H. Adverse events of concurrent immune checkpoint inhibitors and antiangiogenic agents: a systematic review. Front Pharmacol 2019;10:1173.
179. Reck M, Mok TSK, Nishio M, Jotte RM, Cappuzzo F, OrlandiF, et al. Atezolizumab plus bevacizumab and chemotherapy in non-small-cell lung cancer (IMpower150): key subgroup analyses of patients with EGFR mutations or baseline liver metastases in a randomised, open-label phase 3 trial. Lancet Respir Med 2019;7:387-401.
180. Motzer RJ, Penkov K, Haanen J, Rini B, Albiges L, Campbell MT, et al. Avelumab plus axitinib versus sunitinib for advanced renal-cell carcinoma. N Engl J Med 2019;380:1103-15.
181. Paoluzzi L, Cacavio A, Ghesani M, Karambelkar A, Rapkiewicz A, Weber J, et al. Response to anti-PD1 therapy with nivolumab in metastatic sarcomas. Clin Sarcom Res 2016;6:24.
182. McDermott DF, Huseni MA, Atkins MB, Motzer RJ, Rini BI, Escudier B, et al. Clinical activity and molecular correlates of response to atezolizumab alone or in combination with bevacizumab versus sunitinib in renal cell carcinoma. Nat Med 2018;24:749-57.
183. Barker CA, Postow MA, Khan SA, Beal K, Parhar PK, Yamada Y, et al. Concurrent radiotherapy and ipilimumab immunotherapy for patients with melanoma. Cancer Immunol Res 2013;1:92-8.
184. Bang A, Wilhite TJ, Pike LRG, Cagney DN, Aizer AA, Taylor A, et al. Multicenter evaluation of the tolerability of combined treatment with PD-1 and CTLA-4 immune checkpoint inhibitors and palliative radiation therapy. Int J Radiat Oncol Biol Phys 2017;98:344-51.
185. Farha N, Alkhayyat M, Lindsey A, Mansoor E, Saleh MA. Immune checkpoint inhibitor induced colitis: a nationwide population-based study. Clin Res Hepatol Gastroenterol 2022;46:101778.
186. Sanderson K, Scotland R, Lee P, Liu D, Groshen S, Snively J, et al. Autoimmunity in a phase I trial of a fully human anti-cytotoxic T-lymphocyte antigen-4 monoclonal antibody with multiple melanoma peptides and Montanide ISA 51 for patients with resected stages III and IV melanoma. J Clin Oncol 2005;23:741-50.
187. Hasan Ali O, Berner F, Bomze D, Fässler M, Diem S, Cozzio A, et al. Human leukocyte antigen variation is associated with adverse events of checkpoint inhibitors. Eur J Cancer (Oxf, Engl: 1990) 2019;107:8-14.
188. Refae S, Gal J, Ebran N, Otto J, Borchiellini D, Peyrade F, et al. Germinal Immunogenetics predict treatment outcome for PD-1/PD-L1 checkpoint inhibitors. Invest New Drugs 2020;38:160-71.
189. Abdel-Wahab N, Diab A, Yu RK, Futreal A, Criswell LA, Tayar JH, et al. Genetic determinants of immune-related adverse events in patients with melanoma receiving immune checkpoint inhibitors. Cancer Immunol Immunother 2021;70:1939-49.
190. Wang X, Niu X, An N, Sun Y, Chen Z. Comparative efficacy and safety of immunotherapy alone and in combination with chemotherapy for advanced non-small cell lung cancer. Front Oncol 2021;11:611012.
191. Daly LE, Power DG, O’Reilly Á, Donnellan P, Cushen SJ, O’Sullivan K, et al. The impact of body composition parameters on ipilimumab toxicity and survival in patients with metastatic melanoma. Br J Cancer 2017;116:310-7.
192. Bai S, Tian T, Pacheco JM, Tachihara M, Hu P, Zhang J. Immune-related adverse event profile of combination treatment of PD-(L)1 checkpoint inhibitors and bevacizumab in non-small cell lung cancer patients: data from the FDA adverse event reporting system. Transl Lung Cancer Res 2021;10:2614-24.
193. Dubin K, Callahan MK, Ren B, Khanin R, Viale A, Ling L, et al. Intestinal microbiome analyses identify melanoma patients at risk for checkpoint-blockade-induced colitis. Nat Commun 2016;7:10391.
194. Chaput N, Lepage P, Coutzac C, Soularue E, Le Roux K, Monot C, et al. Baseline gut microbiota predicts clinical response and colitis in metastatic melanoma patients treated with ipilimumab. Ann Oncol 2019;30:2012.
195. Westdorp H, Sweep MWD, Gorris MAJ, Hoentjen F, Boers-Sonderen MJ, van der Post RS, et al. Mechanisms of immune checkpoint inhibitor-mediated colitis. Front Immunol 2021;12:768957.
196. Berman D, Parker SM, Siegel J, Chasalow SD, Weber J, Galbraith S, et al. Blockade of cytotoxic T-lymphocyte antigen-4 by ipilimumab results in dysregulation of gastrointestinal immunity in patients with advanced melanoma. Cancer Immun 2010;10:11.
197. Abu-Sbeih H, Herrera LN, Tang T, Altan M, Chaftari AP, Okhuysen PC, et al. Impact of antibiotic therapy on the development and response to treatment of immune checkpoint inhibitor-mediated diarrhea and colitis. J Immunother Cancer 2019;7:242.
198. Manson G, Norwood J, Marabelle A, Kohrt H, Houot R. Biomarkers associated with checkpoint inhibitors. Ann Oncol 2016;27:1199-206.
199. Hommes JW, Verheijden RJ, Suijkerbuijk KPM, Hamann D. Biomarkers of checkpoint inhibitor induced immune-related adverse events - a comprehensive review. Front Oncol 2020;10:585311.
200. Pavan A, Calvetti L, Dal Maso A, Attili I, Del Bianco P, Pasello G, et al. Peripheral blood markers identify risk of immune-related toxicity in advanced non-small cell lung cancer treated with immune-checkpoint inhibitors. Oncologist 2019;24:1128-36.
201. Peng L, Wang Y, Liu F, Qiu X, Zhang X, Fang C, et al. Peripheral blood markers predictive of outcome and immune-related adverse events in advanced non-small cell lung cancer treated with PD-1 inhibitors. Cancer Immunol Immunother 2020;69:1813-22.
202. Fujimoto A, Toyokawa G, Koutake Y, Kimura S, Kawamata Y, Fukuishi K, et al. Association between pretreatment neutrophil-to-lymphocyte ratio and immune-related adverse events due to immune checkpoint inhibitors in patients with non-small cell lung cancer. Thorac Cancer 2021;12:2198-204.
203. Das R, Bar N, Ferreira M, Newman AM, Zhang L, Bailur JK, et al. Early B cell changes predict autoimmunity following combination immune checkpoint blockade. J Clin Investig 2018;128:715-20.
204. Shahabi V, Berman D, Chasalow SD, Wang L, Tsuchihashi Z, Hu B, et al. Gene expression profiling of whole blood in ipilimumab-treated patients for identification of potential biomarkers of immune-related gastrointestinal adverse events. J Transl Med 2013;11:75.
205. Friedlander P, Wood K, Wassmann K, Christenfeld AM, Bhardwaj N, Oh WK. A whole-blood RNA transcript-based gene signature is associated with the development of CTLA-4 blockade-related diarrhea in patients with advanced melanoma treated with the checkpoint inhibitor tremelimumab. J Immunother Cancer 2018;6:90.
206. Tarhini AA, Zahoor H, Lin Y, Malhotra U, Sander C, Butterfield LH, et al. Baseline circulating IL-17 predicts toxicity while TGF-1 and IL-10 are prognostic of relapse in ipilimumab neoadjuvant therapy of melanoma. J Immunother Cancer 2015;3:39.
207. Abu-Sbeih H, Faleck DM, Ricciuti B, Mendelsohn RB, Naqash AR, Cohen JV, et al. Immune checkpoint inhibitor therapy inpatients with preexisting inflammatory bowel disease. J Clin Oncol 2020;38:576-83.
208. Grover S, Ruan AB, Srivoleti P, Giobbie-Hurder A, Braschi-Amirfarzan M, Srivastava A, et al. Safety of immune checkpoint inhibitors in patients with pre-existing inflammatory bowel disease and microscopic colitis. JCO Oncol Pract 2020;16:e933-42.
209. Sleiman J, Wei W, Shah R, Faisal MS, Philpott J, Funchain P. Incidence of immune checkpoint inhibitor-mediated diarrhea and colitis (imDC) in patients with cancer and preexisting inflammatory bowel disease: a propensity score-matched retrospective study. J Immunother Cancer 2021;9:e002567.
210. Meserve J, Facciorusso A, Holmer AK, Annese V, Sandborn WJ, Singh S. Systematic review with meta-analysis: safety and tolerability of immune checkpoint inhibitors in patients with pre-existing inflammatory bowel diseases. Aliment Pharmacol Therap 2021;53:374-82.
211. Wang Y, Abu-Sbeih H, Mao E, Ali N, Qiao W, Trinh VA, et al. Endoscopic and histologic features of immune checkpoint inhibitor-related colitis. Inflamm Bowel Dis 2018;24:1695-705.
212. Kröner PT, Mody K, Farraye FA. Immune checkpoint inhibitor-related luminal GI adverse events. Gastrointest Endosc 2019;90:881-92.
213. Hayashi Y, Hosoe N, Takabayashi K, Limpias Kamiya KJL, Tsugaru K, Shimozaki K, et al. Clinical, endoscopic, and pathological characteristics of immune checkpoint inhibitor-induced gastroenterocolitis. Dig Dis Sci 2021;66:2129-34.
214. Powell N, Ibraheim H, Raine T, Speight RA, Papa S, Brain O, et al. British Society of Gastroenterology endorsed guidance for the management of immune checkpoint inhibitor-induced enterocolitis. Lancet Gastroenterol Hepatol 2020;5:679-97.
215. Wright AP, Piper MS, Bishu S, Stidham RW. Systematic review and case series: flexible sigmoidoscopy identifies most cases of checkpoint inhibitor-induced colitis. Aliment Pharmacol Therap 2019;49:1474-83.
216. Herlihy JD, Beasley S, Simmelink A, Maddukuri V, Amin A, Kamionek M, et al. Flexible sigmoidoscopy rather than colonoscopy is adequate for the diagnosis of ipilimumab-associated colitis. South Med J 2019;112:154-8.
217. De Silva S, Trieu H, Rajan A, Liang Y, Lin JL, Kidambi TD. Flexible sigmoidoscopy may be sufficient for initial evaluation of suspected immunotherapy-mediated colitis: a cross-sectional study. J Gastroenterol Hepatol 2022;37:284-90.
218. Assarzadegan N, Montgomery E, Anders RA. Immune check-point inhibitor colitis: the flip side of the wonder drugs. Virch Arch 2018;472:125-33.
219. Feakins R, Torres J, Borralho-Nunes P, Burisch J, Cúrdia Gonçalves T, De Ridder L, et al. ECCO topical review on clinicopathological spectrum and differential diagnosis of inflammatory bowel disease. J Crohn’s Colitis 2022;16:343-68.
220. Oble DA, Mino-Kenudson M, Goldsmith J, Hodi FS, Seliem RM, Dranoff G, et al. Alpha-CTLA-4 mAb-associated panenteritis: a histologic and immunohistochemical analysis. Am J Surg Pathol 2008;32:1130-7.
221. Chen JH, Pezhouh MK, Lauwers GY, Masia R. Histopathologic features of colitis due to immunotherapy with anti-PD-1 anti-bodies. Am J Surg Pathol 2017;41:643-54.
222. Bavi P, Butler M, Serra S, Chetty R. Immune modulator-induced changes in the gastrointestinal tract. Histopathology 2017;71:494-6.
223. Kubo T, Hirohashi Y, Keira Y, Akimoto M, Ikeda T, Kikuchi N, et al. Identification of characteristic subepithelial surface granulomatosis in immune-related adverse event-associated enterocolitis. Cancer Sci 2021;112:1320-5.
224. Luoma AM, Suo S, Williams HL, Sharova T, Sullivan K, Manos M, et al. Molecular pathways of colon inflammation induced by cancer immunotherapy. Cell 2020;182, 655-71.e622.
225. Sasson SC, Slevin SM, Cheung VTF, Nassiri I, Olsson-Brown A, Fryer E, et al. Interferon-gamma-producing CD8(+) tissue resident memory T cells are a targetable hallmark of immune checkpoint inhibitor-colitis. Gastroenterology 2021;161, 1229-44.e1229.
226. Gonzalez RS, Salaria SN, Bohannon CD, Huber AR, Feely MM, Shi C. PD-1 inhibitor gastroenterocolitis: case series and appraisal of ‘immunomodulatory gastroenterocolitis’. Histopathology 2017;70:558-67.
227. Zou F, Wang X, Glitza Oliva IC, McQuade JL, Wang J, Zhang HC, et al. Fecal calprotectin concentration to assess endoscopic and histologic remission in patients with cancer with immune-mediated diarrhea and colitis. J Immunother Cancer 2021;9:e002058.
228. Meling TR, Aabakken L, Røseth A, Osnes M. Faecal calprotectin shedding after short-term treatment with non-steroidal anti-inflammatory drugs. Scand J Gastroenterol 1996;31:339-44.
229. Cohen M. Proton pump inhibitors may cause elevation in faecal calprotectin levels. Br J Gener Pract 2016;66:350.
230. Abu-Sbeih H, Ali FS, Wang Y. Immune-checkpoint inhibitors induced diarrhea and colitis: a review of incidence, pathogenesis and management. Curr Opin Gastroenterol 2020;36:25-32.
231. Durbin SM, Mooradian MJ, Fintelmann FJ, Zubiri L, Chute DF, Kambadakone A, et al. Diagnostic utility of CT for suspected immune checkpoint inhibitor enterocolitis. J Immunother Cancer 2020;8:e001329.
232. Kim KW, Ramaiya NH, Krajewski KM, Shinagare AB, Howard SA, Jagannathan JP, et al. Ipilimumab-associated colitis: CT findings. Am J Roentgenol 2013;200:W468-74.
233. Tirumani SH, Ramaiya NH, Keraliya A, Bailey ND, Ott PA, Hodi FS, et al. Radiographic profiling of immune-related adverse events in advanced melanoma patients treated with ipilimumab. Cancer Immunol Res 2015;3:1185-92.
234. Barina AR, Bashir MR, Howard BA, Hanks BA, Salama AK, Jaffe TA. Isolated recto-sigmoid colitis: a new imaging pattern of ipilimumab-associated colitis. Abdom Radiol (New York) 2016;41:207-14.
235. Widmann G, Nguyen VA, Plaickner J, Jaschke W. Imaging features of toxicities by immune checkpoint inhibitors in cancer therapy. Curr Radiol Rep 2016;5:59.
236. Garcia-Neuer M, Marmarelis ME, Jangi SR, Luke JJ, Ibrahim N, Davis M, et al. Diagnostic comparison of CT scans and colonoscopy for immune-related colitis in ipilimumab-treated advanced melanoma patients. Cancer Immunol Res 2017;5:286-91.
237. Franklin C, Rooms I, Fiedler M, Reis H, Milsch L, Herz S, et al. Cytomegalovirus reactivation in patients with refractory checkpoint inhibitor-induced colitis. Eur J Cancer (Oxf, Engl:1990) 2017;86:248-56.
238. Abu-Sbeih H, Ali FS, Naqash AR, Owen DH, Patel S, Otterson GA, et al. Resumption of immune checkpoint inhibitor therapy after immune-mediated colitis. J Clin Oncol 2019;37:2738-45.
239. Putignani L, Del Chierico F, Vernocchi P, Cicala M, Cucchiara S, Dallapiccola B. Gut microbiota dysbiosis as risk and premorbid factors of IBD and IBS along the childhood-adulthood transition. Inflamm Bowel Dis 2016;22:487-504.
240. Mourad FH, Hashash JG, Kariyawasam VC, Leong RW. Ulcerative colitis and cytomegalovirus infection: from A to Z. J Crohn’s Colitis 2020;14:1162-71.
241. McCutcheon JL, McClain CM, Puzanov I, Smith TA. Infectious colitis associated with ipilimumab therapy. Gastroenterol Res 2014;7:28-31.
242. Ma W, Gong Z, Abu-Sbeih H, Peng Y, Peng F, Zou F, et al. Outcomes of immune checkpoint inhibitor-related diarrhea or colitis in cancer patients with superimposed gastrointestinal infections. Am J Clin Oncol 2021;44:402-8.
243. Eshet Y, Baruch EN, Shapira-Frommer R, Steinberg-Silman Y, Kuznetsov T, Ben-Betzalel G, et al. Clinical significance of pancreatic atrophy induced by immune-checkpoint inhibitors: a case-control study. Cancer Immunol Res 2018;6:1453-8.
244. Badran YR, Shih A, Leet D, Mooradian MJ, Coromilas A, Chen J, et al. Immune checkpoint inhibitor-associated celiac disease. J Immunother Cancer 2020;8:e000958.
245. Champiat S, Lambotte O, Barreau E, Belkhir R, Berdelou A, Carbonnel F, et al. Management of immune checkpoint blockade dysimmune toxicities: a collaborative position paper. Ann Oncol 2016;27:559-74.
246. André T, Shiu KK, Kim TW, Jensen BV, Jensen LH, Punt C, et al. Pembrolizumab in microsatellite-instability-high advanced colorectal cancer. N Engl J Med 2020;383:2207-18.
247. Chau I, Ajani JA, Doki Y, Xu J, Wyrwicz L, Motoyama S, et al. Nivolumab (NIVO) plus chemotherapy (chemo) or ipilimumab (IPI) versus chemo as first-line (1L) treatment for advanced esophageal squamous cell carcinoma (ESCC): expanded efficacy and safety analyses from Check Mate 648. J Clin Oncol 2022;40:4035.
248. Majeed M, Agrawal R, Gandhi S. Diarrhea in a patient receiving chemotherapy. Gastroenterology 2019;157:1492-3.
249. Kuriakose Kuzhiyanjal AJ, Nigam GB, Afzal M. Amelanotic anorectal malignant melanoma in an ulcerative colitis patient: a rare coincidence or a rare association. BMJ Case Rep 2021;14:e240398.
250. Zhang ZG, Hao XS. Diagnosis and treatment of 41 patients with malignant peritoneal mesothelioma. Zhonghua zhong liuza zhi 2004;26:631-3.
251. Khamaysi I, Hajj E. Drug-induced pancreatic atrophy (‘‘the vanishing pancreas’’). Eur J Hepatogastroenterol 2020;10:101-2.
252. Gordon L, Dokouhaki P, Hagel K, Prasad B. Acute kidney injury from immune checkpoint inhibitor use. BMJ Case Rep 2019;12:e231211.
253. Naito T, Nosaka T, Takahashi K, Ofuji K, Matsuda H, Ohtani M, et al. A case of immune checkpoint inhibitor-related colitis with a distinctive endoscopic finding of colonic pseudolipomatosis. Clin J Gastroenterol 2021;14:1431-6.
254. Coit DG, Thompson JA, Albertini MR, Barker C, Carson WE, Contreras C, et al. Cutaneous melanoma, version 2. 2019, NCCN clinical practice guidelines in oncology. J Natl Compreh Cancer Netw 2019;17:367-402.
255. O’Connor A, Marples M, Mulatero C, Hamlin J, Ford AC. Ipilimumab-induced colitis: experience from a tertiary referral center. Therap Adv Gastroenterol 2016;9:457-62.
256. Jain A, Lipson EJ, Sharfman WH, Brant SR, Lazarev MG. Colonic ulcerations may predict steroid-refractory course in patients with ipilimumab-mediated enterocolitis. World J Gastroenterol 2017;23:2023-8.
257. Hillock NT, Heard S, Kichenadasse G, Hill CL, Andrews J. Infliximab for ipilimumab-induced colitis: a series of 13 patients. Asia-Pac J Clin Oncol 2017;13:e284-90.
258. Minor DR, Chin K, Kashani-Sabet M. Infliximab in the treatment of anti-CTLA4 antibody (ipilimumab) induced immune-related colitis. Cancer Biother Radiopharm 2009;24:321-5.
259. Bellaguarda E, Hanauer S. Checkpoint inhibitor-induced colitis. Am J Gastroenterol 2020;115:202-10.
260. Mir R, Shaw HM, Nathan PD. Mycophenolate mofetil along-side high-dose corticosteroids: optimizing the management of combination immune checkpoint inhibitor-induced colitis. Melanoma Res 2019;29:102-6.
261. Choi K, Abu-Sbeih H, Samdani R, Nogueras Gonzalez G, Raju GS, Richards DM, et al. Can immune checkpoint inhibitors induce microscopic colitis or a brand new entity? Inflamm Bowel Dis 2019;25:385-93.
262. Collins M, Michot JM, Danlos FX, Mussini C, Soularue E, Mateus C, et al. Inflammatory gastrointestinal diseases associated withPD-1 blockade antibodies. Ann Oncol 2017;28:2860-5.
263. de Andrea CE, Perez-Gracia JL, Castanon E, Ponz-Sarvise M, Echeveste JI, Melero I, et al. Endoscopical and pathological dissociation in severe colitis induced by immune-checkpoint inhibitors. Oncoimmunology 2020;9:1760676.
264. Hughes MS, Molina GE, Chen ST, Zheng H, Deshpande V, Fadden R, et al. Budesonide treatment for microscopic colitis from immune checkpoint inhibitors. J Immunother Cancer 2019;7:292.
265. Pagès C, Gornet JM, Monsel G, Allez M, Bertheau P, Bagot M, et al. Ipilimumab-induced acute severe colitis treated by infliximab. Melanoma Res 2013;23:227-30.
266. Johnson DH, Zobniw CM, Trinh VA, Ma J, Bassett RL Jr, Abdel-Wahab N, et al. Infliximab associated with faster symptom resolution compared with corticosteroids alone for the management of immune-related enterocolitis. J Immunother Cancer 2018;6:103.
267. Johnston RL, Lutzky J, Chodhry A, Barkin JS. Cytotoxic T-lymphocyte-associated antigen 4 antibody-induced colitis and its management with infliximab. Dig Dis Sci 2009;54:2538-40.
268. Nassri AB, Muenyi V, AlKhasawneh A, Ribeiro BS, Scolapio JS, Malespin M, et al. Ipilimumab and Nivolumab induced steroid-refractory colitis treated with infliximab: a case report. World J Gastrointest Pharmacol Therap 2019;10:29-34.
269. Kadokawa Y, Takagi M, Yoshida T, Tatsumi A, Fujita K, Inoue T, et al. Efficacy and safety of Infliximab for steroid-resistant immune-related adverse events: a retrospective study. Mol Clin Oncol 2021;14:65.
270. Connolly EA, Walker T, Van der Westhuizen A. Impending infliximab access crisis: a case of steroid-refractory, relapsing immunotherapy-induced colitis responsive to infliximab. Intern Med J 2020;50:767-8.
271. Lankes K, Hundorfean G, Harrer T, Pommer AJ, Agaimy A, Angelovska I, et al. Anti-TNF-refractory colitis after checkpoint inhibitor therapy: possible role of CMV-mediated immunopathogenesis. Oncoimmunology 2016;5:e1128611.
272. Horvat TZ, Adel NG, Dang TO, Momtaz P, Postow MA, Callahan MK, et al. Immune-related adverse events, need for systemic immunosuppression, and effects on survival and time to treatment failure in patients with melanoma treated with ipilimumab at memorial Sloan Kettering cancer center. J Clin Oncol 2015;33:3193-8.
273. Arriola E, Wheater M, Karydis I, Thomas G, Ottensmeier C. Infliximab for IPILIMUMAB-related colitis-letter. Clin Cancer Res 2015;21:5642-3.
274. Bishu S, Melia J, Sharfman W, Lao CD, Fecher LA, Higgins PDR. Efficacy and outcome of tofacitinib in immune checkpoint inhibitor colitis. Gastroenterology 2021;160, 932-4.e933.
275. Abu-Sbeih H, Ali FS, Wang X, Mallepally N, Chen E, Altan M, et al. Early introduction of selective immunosuppressive therapy associated with favorable clinical outcomes inpatients with immune checkpoint inhibitor-induced colitis. J Immunother Cancer 2019;7:93.
276. Céspedes Martínez E, Robles Alonso V, Herrera-De Guise C, Mayorga L, Casellas F, Roca-Herrera M, et al. Severe and refractory gastrointestinal toxicity due to immune checkpointinhibitors: clinical experience in a tertiary referral hospital. Rev Esp Enferm Dig 2023;115(10):567-73.
277. Abu-Sbeih H, Ali FS, Alsaadi D, Jennings J, Luo W, Gong Z, et al. Outcomes of vedolizumab therapy in patients with immune checkpoint inhibitor-induced colitis: a multi-center study. J Immunother Cancer 2018;6:142.
278. Burla J, Bluemel S, Biedermann L, Barysch MJ, Dummer R, Levesque MP, et al. Retrospective analysis of treatment and complications of immune checkpoint inhibitor-associated colitis: histological ulcerations as potential predictor fora steroid-refractory disease course. Inflam Intest Dis 2020;5:109-16.
279. Randhawa M, Gaughran G, Archer C, Pavli P, Morey A, Ali S, et al. Vedolizumab in combined immune checkpoint therapy-induced infliximab-refractory colitis in a patient with metastatic melanoma: a case report. World J Clin Oncol 2019;10:350-7.
280. Hsieh AH, Ferman M, Brown MP, Andrews JM. Vedolizumab: a novel treatment for ipilimumab-induced colitis. BMJ Case Rep 2016;2016:bcr2016216641.
281. Bergqvist V, Hertervig E, Gedeon P, Kopljar M, Griph H, Kinhult S, et al. Vedolizumab treatment for immune checkpoint inhibitor-induced enterocolitis. Cancer Immunol Immunother 2017;66:581-92.
282. Iyoda T, Kurita N, Takada A, Watanabe H, Ando M. Resolution of infliximab-refractory nivolumab-induced acute severe enterocolitis after cyclosporine treatment in a patient with non-small cell lung cancer. Am J Case Rep 2018;19:360-4.
283. Esfahani K, Hudson M, Batist G. Tofacitinib for refractory immune-related colitis from PD-1 therapy. N Engl J Med 2020;382:2374-5.
284. Thomas AS, Ma W, Wang Y. Ustekinumab for refractory colitis associated with immune checkpoint inhibitors. N Engl J Med 2021;384:581-3.
285. Weber JS, Hodi FS, Wolchok JD, Topalian SL, Schadendorf D, Larkin J, et al. Safety profile of nivolumab monotherapy: a pooled analysis of patients with advanced melanoma. J Clin Oncol 2017;35:785-92.
286. Loras C, Gisbert JP, Saro MC, Piqueras M, Sánchez-Montes C, Barrio J, et al. Impact of surveillance of hepatitis band hepatitis c in patients with inflammatory bowel disease under anti-TNF therapies: multicenter prospective observational study (REPENTINA 3). J Crohn’s Colitis 2014;8:1529-38.
287. Cabriada JL, Vera I, Domènech E, Barreiro-de Acosta M, Esteve M, Gisbert JP, et al. Recommendations of the Spanish Working Group on Crohn’s Disease and Ulcerative Colitis on the use of anti-tumor necrosis factor drugs in inflammatory bowel disease. Gastroenterol Hepatol 2013;36:127-46.
288. Pesántez D, Seguí E, Ordás I, Viladot M, Arance A. Successful management of refractory immune-mediated enterocolitis with cyclosporine. Eur J Cancer (Oxf, Engl: 1990) 2020;131:37-9.
289. Shirwaikar Thomas A, Lee SE, Shatila M, De Toni EN, Török HP, Ben Khaled N, et al. IL12/23 blockade for refractory immune-mediated colitis: 2-center experience. Am J Gastroenterol 2023;118:1679-83.
290. Perez Del Nogal G, Patel N. Refractory checkpoint inhibitor colitis responsive to ustekinumab. ACG Case Rep J 2022;9:e00946.
291. Holmstroem RB, Dahl EK, Helms M, Nielsen HV, Andersen JB, Bjerrum JT, et al. Tofacitinib and faecal microbiota transplantation in treating checkpoint inhibitor-induced enterocolitis: case report. BMJ Open Gastroenterol 2022;9:e000989.
292. Sleiman J, Brand RM, Pai R, Brand RE, Rhee J, Schwartz M, et al. Mirroring UC care pathways in refractory immune checkpoint inhibitor (ICI)-mediated colitis: distinct features and common pathways. Clin J Gastroenterol 2023;16:680-4.
293. Wang Y, Wiesnoski DH, Helmink BA, Gopalakrishnan V, Choi K, DuPont HL, et al. Fecal microbiota transplantation for refractory immune checkpoint inhibitor-associated colitis. Nat Med 2018;24:1804-8.
294. Menzies AM, Johnson DB, Ramanujam S, Atkinson VG, Wong ANM, Park JJ, et al. Anti-PD-1 therapy in patients with advanced melanoma and preexisting autoimmune disorders or major toxicity with ipilimumab. Ann Oncol 2017;28:368-76.
295. Haanen J, Ernstoff M, Wang Y, Menzies A, Puzanov I, Grivas P, et al. Rechallenge patients with immune checkpoint inhibitors following severe immune-related adverse events: review of the literature and suggested prophylactic strategy. J Immunother Cancer 2020;8:e000604.
296. Zhao Q, Zhang J, Xu L, Yang H, Liang N, Zhang L, et al. Safety and efficacy of the rechallenge of immune checkpoint inhibitors after immune-related adverse events in patients with cancer: a systemic review and meta-analysis. Front Immunol 2021;12:730320.
297. Park R, Lopes L, Saeed A. Outcomes following immunotherapy re-challenge after immune-related adverse event: systematic review and meta-analysis. Immunotherapy 2020;12:1183-93.
298. de Malet A, Antoni G, Collins M, Soularue E, Marthey L, Vaysse T, et al. Evolution and recurrence of gastrointestinal immune-related adverse events induced by immune checkpoint inhibitors. Eur J Cancer (Oxf, Engl: 1990) 2019;106:106-14.
299. Allouchery M, Lombard T, Martin M, Rouby F, Sassier M, Bertin C, et al. Safety of immune checkpoint inhibitor rechallenge after discontinuation for grade ≥ 2 immune-related adverse events in patients with cancer. J Immunother Cancer 2020:8.
300. Siddiqui BA, Gheeya JS, Goswamy R, Bathala TK, Surasi DS, Gao J, et al. Durable responses in patients with genitourinary cancers following immune checkpoint therapy rechallenge after moderate-to-severe immune-related adverse events. J Immunother Cancer 2021;9:e002850.
301. Kartolo A, Holstead R, Khalid S, Emack J, Hopman W, Baetz T. Safety of immunotherapy rechallenge after immune-related adverse events in patients with advanced cancer. J Immunother (Hagerstown, Md: 1997) 2021;44:41-8.
302. Thompson JA, Hamid O, Minor D, Amin A, Ron IG, Ridolfi R, et al. Ipilimumab in treatment-naive and previously treated patients with metastatic melanoma: retrospective analysis of efficacy and safety data from a phase II trial. J Immunother (Hagerstown, Md: 1997) 2012;35:73-7.
303. Abu-Sbeih H, Ali FS, Qiao W, Lu Y, Patel S, Diab A, et al. Immune checkpoint inhibitor-induced colitis as a predictor of survival in metastatic melanoma. Cancer Immunol Immunother 2019;68:553-61.
304. Carmona-Bayonas A, Jimenez-Fonseca P, Fernández-Somoano A, Álvarez-Manceñido F, Castañón E, Custodio A, et al. Top ten errors of statistical analysis in observational studies for cancer research. Clin Transl Oncol 2018;20:954-65.
305. Eggermont AMM, Kicinski M, Blank CU, Mandala M, Long GV, Atkinson V, et al. Association between immune-related adverse events and recurrence-free survival among patients with stage III melanoma randomized to receive pembrolizumab or placebo: a secondary analysis of a randomized clinical trial. JAMA Oncol 2020;6:519-27.
306. Verzoni E, Cartenì G, Cortesi E, Giannarelli D, De Giglio A, Sabbatini R, et al. Real-world efficacy and safety of nivolumab in previously-treated metastatic renal cell carcinoma, and association between immune-related adverse events and survival: the Italian expanded access program. J Immunother Cancer 2019;7:99.
307. Maher VE, Fernandes LL, Weinstock C, Tang S, Agarwal S, Brave M, et al. Analysis of the association between adverse event sand outcome in patients receiving a programmed death protein 1 or programmed death ligand 1 antibody. J Clin Oncol 2019;37:2730-7.
308. Schweizer C, Schubert P, Rutzner S, Eckstein M, Haderlein M, Lettmaier S, et al. Prospective evaluation of the prognostic value of immune-related adverse events in patients with non-melanoma solid tumour treated with PD-1/PD-L1 inhibitors alone and in combination with radiotherapy. Eur J Cancer (Oxf, Engl: 1990) 2020;140:55-62.
309. Maillet D, Corbaux P, Stelmes JJ, Dalle S, Locatelli-Sanchez M, Perier-Muzet M, et al. Association between immune-related adverse events and long-term survival outcomes in patients treated with immune checkpoint inhibitors. Eur J Cancer (Oxf, Engl: 1990) 2020;132:61-70.
310. Zhou X, Yao Z, Yang H, Liang N, Zhang X, Zhang F. Are immune-related adverse events associated with the efficacy of immune checkpoint inhibitors in patients with cancer? A systematic review and meta-analysis. BMC Med 2020;18:87.
311. Cheung V, Gupta T, Ye W, Middleton M, Fairfax B, Payne M, et al. PTU-061 immunotherapy-related gastritis in a tertiary oncology centre. Gut 2019;68:A147.
312. Tang T, Abu-Sbeih H, Luo W, Lum P, Qiao W, Bresalier RS, et al. Upper gastrointestinal symptoms and associated endoscopic and histological features in patients receiving immune checkpoint inhibitors. Scand J Gastroenterol 2019;54:538-45.
313. Johncilla M, Grover S, Zhang X, Jain D, Srivastava A. Morphological spectrum of immune checkpoint inhibitor therapy-associated gastritis. Histopathology 2020;76:531-9.
314. Vandepapelière J, Siplet J, Libbrecht L, Dano H, Baurain JF, Moreels T. Auto-immune gastritis induced by pembrolizumab, an anti-PD-1, in a melanoma patient. Acta Gastroenterol Belg 2020;83:482-4.
315. Boike J, Dejulio T. Severe esophagitis and gastritis from nivolumab therapy. ACG Case Rep J 2017;4:e57.
316. Horisberger A, La Rosa S, Zurcher JP, Zimmermann S, Spertini F, Coukos G, et al. A severe case of refractory esophageal stenosis induced by nivolumab and responding to tocilizumab therapy. J Immunother Cancer 2018;6:156.
317. Lu J, Firpi-Morell RJ, Dang LH, Lai J, Liu X. An unusual case of gastritis in one patient receiving PD-1 blocking therapy: coexisting immune-related gastritis and cytomegaloviral infection. Gastroenterol Res 2018;11:383-7.
318. Hulo P, Touchefeu Y, Cauchin E, Archambeaud I, Chapelle N, Bossard C, et al. Acute ulceronecrotic gastritis with cytomegalovirus reactivation: uncommon toxicity of immune checkpoint inhibitors in microsatellite instability-high metastatic colorectal cancer. Clin Colorect Cancer 2020;19:e183-8.
319. Townsend MJ, Liu M, Giobbie-Hurder A, Sack JS, LeBoeuf NR, Hodi FS, et al. Pancreatitis and hyperlipasemia in the setting of immune checkpoint inhibitor therapy. J Natl Compreh Cancer Netw 2023;21, 831-40.e833.
320. Zhao Z, Zhang W, Pang L, Zeng L, Liu S, Liu J. Pancreatic adverse events of immune checkpoint inhibitors therapy for solid cancer patients: a systematic review and meta-analysis. Front Immunol 2023;14:1166299.